Craft

Memo Therapeutics

Total Funding

$50.5 M

Memo Therapeutics Summary

Company Summary

Overview
Memo Therapeutics is a company operating in the field of antibody discovery and immune repertoire analysis. Its DROPZYLLA platform creates a recombinant in vitro copy of an individual’s B cell and antibody repertoire, which is then banked as a library. The company develops a therapeutic antibody lead pipeline with an initial focus on infectious diseases and cancer.
Type
Private
Status
Active
Founded
2012
HQ
Schlieren, CH | view all locations
Website
https://memo-therapeutics.com/home.html
Cybersecurity rating
Sectors

Key People

  • Karsten Fischer

    Karsten Fischer, CEO

    • Christoph Esslinger

      Christoph Esslinger, CSO, Board Member

      • Simone Schmitt

        Simone Schmitt, Director Antibody Development

        • Robert Schier, Director

          LocationsView all

          1 location detected

          • Schlieren, ZH HQ

            Switzerland

            Wagistrasse 27

          Footer menu